Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) was a Phase II multi-centre, single arm, non-randomised, open-label copper-64 labelled SAR-Bombesin PET imaging trial of ...

SpaceOAR Hydrogel is a polyethylene glycol–based hydrogel designed to create space between the prostate and rectum to reduce the radiation dose to the rectum during radiation therapy for prostate ...

Rural men had almost twice the risk of prostate cancer biochemical recurrence as urban men in the US. Patients living in rural areas may be at an increased risk for prostate cancer biochemical ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

SBRT after radical prostatectomy without ADT improves prostate cancer BCRFS and appears to be a viable alternative to conventionally fractionated radiation therapy, a phase 2 trial finds. After ...